BIOCRYST PHARMACEUTICALS INC (BCRX)

Current Report Filed: 2026-05-06

Key Insights

BioCryst announced Q1 2026 financial results and corporate developments on May 6, 2026, indicating the company is actively managing operations and maintaining investor communication through earnings releases.
The filing indicates a conference call and webcast were scheduled to discuss financial results and corporate developments, suggesting management engagement with investors regarding business performance and strategy.
The press release was furnished under Regulation FD Disclosure, meaning the information is being simultaneously disclosed to all investors to ensure fair and equal access to material information.

Quarterly Report Filed: 2026-05-06

Key Insights

The filing contains extensive structured data references for multiple revenue segments including ORLADEYO (primary product), Peramivir, and license/collaborative R&D arrangements, indicating diversified revenue streams but requiring detailed review of actual financial metrics.
Multiple references to the Astria acquisition (dated 2026-01-23) suggest a significant corporate transaction completed in Q1 2026, which will materially impact operating expenses, R&D costs, and SG&A expenses for the quarter.
The filing shows geographic concentration risk data for US sales and detailed fair value measurements across multiple investment security types (money market funds, government agencies, corporate debt), indicating active treasury management and potential liquidity considerations.
References to royalty arrangements with RPI 2019 Intermediate Finance Trust tied to ORLADEYO sales at multiple tiers (under $350K, $350K-$550K, over $550K annually) demonstrate structured revenue-sharing obligations that will impact net margins as sales scale.

Insider Trading Filed: 2026-04-07

Key Insights

Sandeep Menon, the Chief R&D Officer, has received a significant inducement grant of 205,150 restricted stock units and 441,350 stock options, indicating the company's commitment to R&D efforts and incentivizing the executive's long-term involvement.
The option grant has a 10-year term and vests over 4 years, aligning Menon's interests with long-term shareholder value creation.
The sizeable insider stock acquisition suggests Menon's confidence in the company's future prospects and may signal positive sentiment about the company's R&D pipeline and growth potential.

Insider Trading Filed: 2026-03-24

Key Insights

Theresa Heggie, a director at BioCryst Pharmaceuticals, exercised 49,933 stock options and sold the same amount of shares on March 20, 2026.
The stock options were exercised at $6.30 per share, and the shares were sold at a weighted average price of $10.11 per share, indicating potential profit-taking.
The transaction resulted in Heggie's direct ownership decreasing from 115,285 shares to 65,352 shares, a 43% reduction in her direct holdings.

Insider Trading Filed: 2026-03-18

Key Insights

The reporting person, Alane P. Barnes, exercised 150,000 stock options and sold the same number of shares in a planned transaction, indicating an ongoing equity incentive program at the company.
The sale was executed at a weighted average price of $9.15, which represents a gain of over 60% from the $5.51 exercise price, suggesting the stock has been performing well.
The reporting person continues to hold a significant stake of 400,703 shares in the company, indicating their commitment to the long-term success of the business.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Amy E. McKee, acquired 642 shares of common stock in BIOCRYST PHARMACEUTICALS INC (BCRX) on February 27, 2026, which increased her direct ownership to 42,432 shares.
This share acquisition was made in lieu of 50% of the quarterly cash board member retainer, suggesting the reporting person's continued commitment to the company.
The transaction price of $8.75 per share indicates the reporting person's confidence in the company's valuation and future prospects.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Steven Frank, acquired 1,285 shares of BiocrystPharmaceuticals common stock on February 27, 2026, increasing his direct beneficial ownership to 18,903 shares.
The shares were acquired in lieu of 100% of his quarterly cash board member retainer of $11,250, indicating his commitment to the company.
Insider buying, especially by a director, can be a positive signal about the company's prospects and the director's confidence in the stock.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Vincent Milano, has acquired 848 shares of BiocrystPharmaceuticals common stock, increasing his direct ownership to 92,067 shares.
The shares were acquired in lieu of 50% of Milano's quarterly cash board retainer and board chair retainer, suggesting he is compensated partially in stock.
Insider buying by a director can signal confidence in the company's future performance and may be viewed positively by investors.

Insider Trading Filed: 2026-03-03

Key Insights

Insider Jon P. Stonehouse, a director of BioDecryst Pharmaceuticals, has engaged in a significant transaction involving the company's stock, including exercising stock options and selling shares.
Stonehouse exercised 305,995 stock options at a price of $3.22 and then sold the same number of shares at a weighted average price of $8.64, generating substantial gains.
The transaction appears to be part of a pre-established trading plan, suggesting it may not be a discretionary trade, but rather an automated execution based on a previously established plan.

Insider Trading Filed: 2026-03-03

Key Insights

Jill C. Milne, a director of BioCryst Pharmaceuticals, acquired 528 shares of common stock through a transaction on 2/27/2026, increasing her direct ownership to 15,382 shares.
The shares were acquired at $8.75 per share, which appears to be a standard non-cash compensation for the director's board retainer.
Insider transactions can provide insights into management's confidence in the company's prospects, though a single purchase should not be over-interpreted.

Current Report Filed: 2026-02-26

Key Insights

BioCryst Pharmaceuticals reported its full year 2025 financial results, which appear to show continued growth and development of the company's pipeline.
The company highlighted recent corporate developments, which may indicate progress on key initiatives or products.
Investors will likely be interested in the details provided on the conference call and webcast, which could provide more insights into the company's performance and outlook.

Annual Report Filed: 2026-02-26

Key Insights

BioCryst Pharmaceuticals reported a decline in product revenues for 2025 compared to the prior year, indicating potential challenges in its key commercial products.
The company recorded an increase in license and other revenues, suggesting progress in its licensing and collaboration agreements, which could provide additional revenue streams.
BioCryst Pharmaceuticals divested its Irish subsidiary, BioCryst Ireland, in 2025, potentially streamlining its operations and focusing on core business activities.

Insider Trading Filed: 2026-01-27

Key Insights

Jill C. Milne, a director of BioCryst Pharmaceuticals, acquired additional shares of the company's common stock through an automatic non-employee director grant, indicating ongoing commitment to the organization.
The acquisition of Astria Therapeutics resulted in Milne receiving 2,582 shares of BioCryst common stock in exchange for her Astria shares, further increasing her ownership stake.
The automatic grant of 26,684 stock options to Milne, vesting over a 3-year period, aligns her incentives with long-term shareholder value creation.

Current Report Filed: 2026-01-23

Key Insights

BioCryst Pharmaceuticals has secured a $400 million term loan facility from Blackstone to finance the merger and provide working capital.
The term loan has a 5-year maturity with quarterly interest-only payments, and BioCryst has the option to capitalize a portion of the interest during the first 2 years.
The loan agreement includes customary covenants and events of default, which could restrict BioCryst's financial and operational flexibility if not met.

Current Report Filed: 2026-01-12

Key Insights

BioCryst Pharmaceuticals reported strong preliminary Q4 2025 and full year 2025 ORLADEYO net revenue, beating prior guidance and showing significant year-over-year growth.
The company provided guidance for full year 2026 ORLADEYO net revenue, total revenue, and operating expenses, giving investors visibility into the company's future performance.
BioCryst has a substantial cash position of $338 million as of December 31, 2025, providing ample resources to fund its operations and growth initiatives.

Current Report Filed: 2026-01-09

Key Insights

BioCryst Pharmaceuticals is increasing the wholesale acquisition cost (WAC) for its drug ORLADEYO by 9% from $44,484.33 to $48,487.92 per 28-day pack.
The price increase may positively impact the company's revenue and profitability, but could also affect patient access and affordability of the drug.
Investors should closely monitor the market reaction and potential impact on ORLADEYO sales volume and the company's overall financial performance.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information